CXCL13 Protein (AA 22-109)

Catalog No. ABIN2666443

This Recombinant CXCL13 protein is produced in Escherichia coli (E. coli).

Quick Overview for CXCL13 Protein (AA 22-109) (ABIN2666443)

Target: CXCL13 (Chemokine (C-X-C Motif) Ligand 13 (CXCL13))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: Intracellular Flow Cytometry (ICFC)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 22-109

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract BaF3-mCXCR5 transfectants in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in buffer containing carrier protein such as 1 % BSA or HSA or 10 % FBS. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored at -20°C or -70°C for six months.

Target Details

Target: CXCL13 (Chemokine (C-X-C Motif) Ligand 13 (CXCL13))

Alternative Name: CXCL13

Background: CXCL13 was initially described as a chemokine, highly expressed in the follicles of Peyer's patches, spleen, and lymph nodes, and as a strong chomoattractant for B cells. CXCL13 is expressed by T follicular helper cells, dendritic cells, and stromal cells (including marginal reticular cells (MRCs) and follicular dendritic cells (FDCs)) in B cell areas of secondary lymphoid tissue. CXCL13 binds to CXCR5 that was initially cloned from Burkitt's lymphoma cells and named BLR1. B cells migrate in lymphoid organs in search of specific antigens. B cells enter lymph nodes through high endothelial venules and migrate through the lymph node follicle in a CXCL13/CXCR5 dependent manner. During the B cell migration in the follicle, they are in contact with FDCs, MRCs, and cells localized around the follicle perimeter, such as sinus-associated macrophages and T cell zone-associated DCs. Subsequent to the migration though the FDC network, the B cells travel though the T cell zone-proximal follicle. In this migration, CCL21, CCL19, CCR7 and CXCR5 are involved. CXCL13, CCL19, and CCL21 take part in the formation of tertiary lymphoid tissues in chronic antigen-induced arthritis. High expression of CXCL13 has been linked to lupus, Helicobacter pylori-associated gastritis, multiple sclerosis, rheumatoid arthritis, and the allergic airway inflammatory process. In summary, CXCL13 is highly expressed at sites of new lymphoid tissue formation in a variety of chronic inflammatory conditions.

Molecular Weight: The 78 amino acid recombinant protein has a predicted molecular mass of approximately 9.79 kDa. The DTT-reduced and non-reduced protein migrate at approximately 15 and 13 kDa by SDS-PAGE respectively. The N-terminal amino acid is Ile.